TMCnet News
Pulmonx to Participate in Upcoming Investor ConferencesREDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Stifel 2026 Healthcare Conference Live and archived webcasts of the fireside chats will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx Corporation ulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD).?Pulmonx’s?Zephyr® Endobronchial Valve,?Chartis® Pulmonary Assessment System, LungTraX®?Platform, and?StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr® Endobronchial Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option?for improving breathing,?activity?and quality of life in patients with severe emphysema. For more information on?the Zephyr?Valves and the company, please visit?www.Pulmonx.com.? Pulmonx®,?AeriSeal®,?Chartis®, LungTraX®,?StratX®, and Zephyr® are registered?trademarks of Pulmonx Corporation.? Contact 
|
